BOSTON — eClinical Solutions LLC, a global provider of digital clinical software and services, has expanded its executive leadership team with the appointment of Lauren Whitsell as Chief Operating Officer and Venu Mallarapu as Chief Transformation and AI Officer.
The company said the leadership additions come as it prepares for its next phase of growth following a recent investment from GI Partners, with plans to deepen its product roadmap, further embed artificial intelligence and risk-based capabilities, and support more advanced clinical trial operations.
Whitsell brings more than two decades of experience in technology and healthcare, with a background in operational leadership and scaling companies and systems. She joins eClinical Solutions from STARLIMS, where she served as Chief Product and Operations Officer and led global product development, implementation and support efforts for the company’s laboratory information management systems. Before STARLIMS, she held operational leadership roles at Appriss Health and Appriss Insights prior to the companies’ acquisition by Equifax Workforce Solutions.
“As eClinical Solutions focuses on innovating the future of clinical trial automation, scaling operations and driving internal efficiencies that mirror the expectations of our customers is equally critical to maintaining our market-leading capabilities,” said Lauren Whitsell, COO of eClinical Solutions. “I’m passionate about technology, efficiency, and growth that will support the end-to-end clinical research lifecycle.”
In her new role, Whitsell will oversee executive leadership of all post-sale functions across the business, including professional services, implementation, support, training, adoption and offshore operations. She will also focus on strengthening customer service and operational performance across the organization.
Mallarapu, who previously served as Executive Vice President of Global Operations at eClinical Solutions, will lead the company’s AI-first strategy as Chief Transformation and AI Officer. His role will focus on integrating artificial intelligence and automation across technology and business processes to support workforce transformation and enhance the customer experience.
During his tenure at the company, Mallarapu helped expand the firm’s global delivery organization and partner ecosystem as eClinical Solutions grew its customer base, which now includes 18 of the top 50 pharmaceutical companies worldwide.
“Over the last four years, I’ve seen firsthand how eClinical Solutions has evolved elluminate® to an end-to-end clinical data intelligence platform to achieve trial outcomes,” said Venu Mallarapu, Chief Transformation and AI Officer at eClinical Solutions. “eClinical is shifting clinical data chaos into actionable decisions for biopharma leaders, especially in expanding our elluminate agents, which are fueled by data products with shared context and workflows and a foundation with grounding guardrails and policies. Internally, we are taking a similar approach to unite intentional AI strategy and innovation for operational transformation. I’m focused on building the AI and operational foundation that sets the standard for how clinical data companies run and win in the next decade.”
Chief Executive Officer and co-founder Raj Indupuri said the expanded leadership team will help guide the company’s long-term strategy as it scales its clinical data intelligence platform.
“When eClinical Solutions was founded in 2012, we had a vision to help solve the industry’s clinical data challenges. We leveraged our deep expertise in clinical data and biometrics services to evolve the elluminate platform, enhanced by collaborations – including ZS and Snowflake – and driven by our expanding C-suite of experts,” said Raj Indupuri, CEO and co-founder of eClinical Solutions. “Our infrastructure continues to scale, from deploying AI agents to enabling integrated risk management. We are committed to delivering value for biopharma and CRO organizations in alignment with our founding vision to help the life sciences industry reduce cycle times, improve quality, and bring breakthrough therapies to patients faster. I look forward to the support Lauren and Venu provide as we continue in our growth journey.”
